Venn Life Sciences Holdings PLC Innovenn Board Appointment

TIDMVENN

Venn Life Sciences Holdings PLC

10 December 2014

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Innovenn Board Appointment

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the appointment of Gill Leates as Non-Executive Director to the board of its subsidiary, Innovenn, with immediate effect. The appointment was approved by the board of Venn last week and comes on the back of the recent commencement of production of its breakthrough skin research model, Labskin.

Gill brings extensive public market experience to Innovenn having served as Investment Director on the main board of Majedie Investments PLC from 1999 to 2008, and as a non-executive director of Majedie Asset Management Limited during that period, where she played a key role in setting up the UK pension fund management business in 2002 and is now managing over GBP5bn. Prior to that she successfully managed GBP1bn in the UK stock market for Courtaulds Pension Fund. Whilst in her early career from 1981 to 1989 she worked at Schroders on researching the US and UK, in corporate finance, and then successfully managing the Schroders UK Smaller Companies Exempt Fund. Since 2009 Gill has been a non-executive Director of Hydrodec PLC, and is currently chairman of its Audit Committee, and member of its Remuneration and Nomination Committees. In March 2014 she was also appointed as non-executive Chairman of Verdes Management PLC.

Commenting on the appointment, Venn CEO, Tony Richardson, said: "We are very pleased to welcome Gill to the Board of Innovenn as a Non-Executive Director. Gill's experience with public companies and investment strategies fits exactly with our vision to develop Innovenn as a leading skin science organisation."

 
 Venn Life Sciences Holdings Plc                      www.vennlifesciences.com 
 Tony Richardson, Chief Executive                         Tel: [phone] 
  Officer 
 Declan Service, Managing Director                         Tel: [phone] 
 Orla McGuinness                                          Tel: [phone] 
 
 Zeus Capital (Nominated Adviser 
  and Broker) 
 Ross Andrews/Andrew Jones                                  Tel: [phone] 
 Dominic Wilson                                             Tel: [phone] 
 
 Walbrook PR Ltd                     Tel: [phone] or [e-mail] 
 Paul McManus                                               Mob: [phone] 
 Lianne Cawthorne                                           Mob: [phone] 
 

About Innovenn

Innovenn (55.6% owned by Venn) is a market development accelerator dedicated to rapidly commercialising proven scientific breakthroughs in the form of products and technologies primarily in Skin Science. These include Labskin the breakthrough research grade human skin testing platform as well as the clinically proven Blemish Control Technology for the professional skincare market. For more information on Innovenn, visit www.innovenn.co.uk

About Venn Life Sciences Limited

Venn Life Sciences is a Clinical Research Organisation providing clinical trial management solutions and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK and Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn recently established an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRALFFELFRLAIIS